Tags

Type your tag names separated by a space and hit enter

Sesamol suppresses neuro-inflammatory cascade in experimental model of diabetic neuropathy.
J Pain. 2010 Oct; 11(10):950-7.JP

Abstract

Development of tolerance, inadequate relief, and potential toxicity of classical antinociceptives warrant the investigation of the newer agents to relieve diabetic neuropathic pain. The aim of the present study was to explore the effect of sesamol on thermal and mechanical hyperalgesia, allodynia, oxidative-nitrosative stress, inflammation, and apoptosis in STZ-induced experimental diabetes. Diabetic rats developed neuropathy, which was evident from a marked hyperalgesia and allodynia associated with enhanced nitrosative stress, release of inflammatory mediators (TNF-α, IL-1β, TGF-1β), and caspase 3. Chronic treatment with sesamol (2, 4, and 8 mg/kg body weight; po) for 4 weeks starting from the 4th week of STZ injection significantly attenuated behavioral, biochemical, and molecular changes associated with diabetic neuropathy. Moreover, diabetic rats treated with insulin-sesamol combination produced more pronounced beneficial effect as compared to their per se groups. The major finding of the study is that insulin alone corrected the hyperglycemia and partially reversed the pain response in diabetic rats. However, the combination with sesamol not only attenuated the diabetic condition but also reversed neuropathic pain through modulation of oxidative-nitrosative stress, inflammatory cytokine release, and caspase-3 in diabetic rats, and thus it may find clinical application to treat neuropathic pain in the diabetic patient.

PERSPECTIVE

This study shows the beneficial effect of sesamol on neuropathic pain through modulation of oxidative-nitrosative stress, inflammatory cytokine release, and caspase-3 in diabetic rats, and thus it may find clinical application to treat neuropathic pain in the diabetic patient.

Authors+Show Affiliations

Pharmacology Research Laboratory, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab University, Chandigarh, India. dr_chopra_k@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20418182

Citation

Chopra, Kanwaljit, et al. "Sesamol Suppresses Neuro-inflammatory Cascade in Experimental Model of Diabetic Neuropathy." The Journal of Pain : Official Journal of the American Pain Society, vol. 11, no. 10, 2010, pp. 950-7.
Chopra K, Tiwari V, Arora V, et al. Sesamol suppresses neuro-inflammatory cascade in experimental model of diabetic neuropathy. J Pain. 2010;11(10):950-7.
Chopra, K., Tiwari, V., Arora, V., & Kuhad, A. (2010). Sesamol suppresses neuro-inflammatory cascade in experimental model of diabetic neuropathy. The Journal of Pain : Official Journal of the American Pain Society, 11(10), 950-7. https://doi.org/10.1016/j.jpain.2010.01.006
Chopra K, et al. Sesamol Suppresses Neuro-inflammatory Cascade in Experimental Model of Diabetic Neuropathy. J Pain. 2010;11(10):950-7. PubMed PMID: 20418182.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sesamol suppresses neuro-inflammatory cascade in experimental model of diabetic neuropathy. AU - Chopra,Kanwaljit, AU - Tiwari,Vinod, AU - Arora,Vipin, AU - Kuhad,Anurag, Y1 - 2010/04/24/ PY - 2009/06/29/received PY - 2009/12/16/revised PY - 2010/01/01/accepted PY - 2010/4/27/entrez PY - 2010/4/27/pubmed PY - 2011/7/20/medline SP - 950 EP - 7 JF - The journal of pain : official journal of the American Pain Society JO - J Pain VL - 11 IS - 10 N2 - UNLABELLED: Development of tolerance, inadequate relief, and potential toxicity of classical antinociceptives warrant the investigation of the newer agents to relieve diabetic neuropathic pain. The aim of the present study was to explore the effect of sesamol on thermal and mechanical hyperalgesia, allodynia, oxidative-nitrosative stress, inflammation, and apoptosis in STZ-induced experimental diabetes. Diabetic rats developed neuropathy, which was evident from a marked hyperalgesia and allodynia associated with enhanced nitrosative stress, release of inflammatory mediators (TNF-α, IL-1β, TGF-1β), and caspase 3. Chronic treatment with sesamol (2, 4, and 8 mg/kg body weight; po) for 4 weeks starting from the 4th week of STZ injection significantly attenuated behavioral, biochemical, and molecular changes associated with diabetic neuropathy. Moreover, diabetic rats treated with insulin-sesamol combination produced more pronounced beneficial effect as compared to their per se groups. The major finding of the study is that insulin alone corrected the hyperglycemia and partially reversed the pain response in diabetic rats. However, the combination with sesamol not only attenuated the diabetic condition but also reversed neuropathic pain through modulation of oxidative-nitrosative stress, inflammatory cytokine release, and caspase-3 in diabetic rats, and thus it may find clinical application to treat neuropathic pain in the diabetic patient. PERSPECTIVE: This study shows the beneficial effect of sesamol on neuropathic pain through modulation of oxidative-nitrosative stress, inflammatory cytokine release, and caspase-3 in diabetic rats, and thus it may find clinical application to treat neuropathic pain in the diabetic patient. SN - 1528-8447 UR - https://www.unboundmedicine.com/medline/citation/20418182/Sesamol_suppresses_neuro_inflammatory_cascade_in_experimental_model_of_diabetic_neuropathy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1526-5900(10)00021-0 DB - PRIME DP - Unbound Medicine ER -